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Abstract 
Eukaryotic cells contain an extensive amount of GTP/GDP binding proteins. Proteins 
known as Ras GTPase primary function as a binary switch, where they cycle from an on and off 
state when GTP or GDP are bound, respectively. They are known to play a critical role in many 
cellular functions where a dysregulation could potentially lead to oncogenic behavior or other 
malignancies. In our laboratory, our focus is the study of a Ras related protein Cell division 
control 42 homolog (Cdc42) which belongs to the Rho subfamily. Cdc42 plays a critical role in 
many biological signaling processes; therefore, its uncontrol gene expression has been known to 
play a pivotal role in cancer cell progression and metastasis. A single point mutation was done 
on Cdc42 where a Threonine(T) was replaced to an Alanine(A) at position 35 (Cdc42(T35A)), 
this demonstrated a decrease in the flexibility in a region that is important for the interactions of 
downstream effector proteins.1 AZA197 has been demonstrated to show selectivity to Cdc42 and 
inhibit colon rectal tumor growth.2 The purpose of this research was to successfully synthesize 
the small molecule, AZA197, and study its interaction with Cdc42. Fluorescence spectroscopy 
was used in both characterizations of Cdc42(WT) and Cdc42(T35A) interactions with AZA197. 
The data suggest that in the presence of AZA197 Cdc42(WT) is more resistant to protein 
denaturation and has an increase in the Gibbs free energy of unfolding in the absence of GnHCl. 
Results also highlighted that AZA197 also interacts with Cdc42(T35A) and may have a 
destabilizing effect on this Cdc42 variant. 
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Chapter I-Introduction 
Ras proteins 
Ras or Rat Sarcoma genes were first identified and characterized as transduced oncogenes.3 
The Ras protein family is composed of small molecular weight GTPase proteins that contribute 
to a series of diverse biological roles upon interaction with specific regulatory and effector 
proteins. GTPase proteins primarily function as molecular switches, as they cycle between 
Guanosine Triphosphate (GTP) and Guanosine Diphosphate (GDP), known as the on and off 
states, respectively. The Human Ras superfamily contains 153 protein members, that contribute 
to various signal transduction pathways, making them a perfect candidate to study protein-
protein interactions.4, 5 They also have the potential to be utilized as targets for therapeutic 
treatments such as cancer or other diseases. 
The Ras superfamily are a GTPase protein characterized by a Gbox domain that is found on 
the N-terminal side that is responsible for the GTP binding and hydrolysis biochemical activity.3, 
4, 6 The “G box” is separated into five different segments, G1-G5, involving the GTP/GDP 
binding region, and an active site for the common mechanism of GTPase proteins. The G1 box is 
known as the P-loop, a purine nucleotide binding region.3, 6The G2 box has a Threonine residue 
at position 35, that is highly conserved among the Ras superfamily.3 The G3 box sequence has an 
aspartic acid residue, responsible for participating in the binding of a nucleotide-associated Mg2+ 
ion.3, 6 The G4 box plays a role in the hydrogen bonding of the guanine ring, providing the 
stabilizing interactions within the G1 box.3 The G5 box is the least conserved among the 
superfamily and it’s believed to be involved in indirect associations with the guanine nucleotide.3 
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Rho Proteins 
Rho proteins are a subfamily within Ras proteins that contain a highly conserved region 
within the G box.7 Nonetheless, some members of this group are uniquely differentiated by 
containing a specific sequence among all Ras superfamily proteins.3, 8 They are low molecular 
weight proteins that are mainly found in the cytoplasm.3, 8 Rho proteins are divided into six 
different families based on sequence similarities and are further characterized into typical and 
atypical GTPases depending upon its mode of regulation.5 
The Rho GTPases family contributes to cellular processes such as: organization of actin and 
microtubules in the cytoskeleton, regulation of gene expression, vesicle trafficking, cell cycle 
progression, cell morphogenesis, cell polarity, and cell migration.5, 9, 10 In addition, Rho proteins 
are  involved in inflammation process, wound repairs, and cancer progression.9 
Specifically, the human Rho family is composed of 23 proteins that are divided into 8 
categories depending on their type of regulation, typical or atypical.11 Typical regulation refers to 
the GTPase proteins dependency on Guanine nucleotide exchange factors (GEFs) and GTPase 
activating proteins (GAPs).9 Atypical regulation of GTPase protein do not depend on regulatory 
proteins but are believed to use post-translational modifications for its regulation and 
expression.9 
Typical regulation of Rho proteins rely on three main effector proteins: GAPs, GEFs, and 
Guanine nucleotide dissociation inhibitors (GDIs).5, 8, 9 As mentioned above, GTPase proteins 
cycle between an active and inactive state, GTP and GDP, respectively. GEFs are proteins that 
facilitate the exchange of GDP (inactive) to GTP (active). GAPs are responsible for facilitating 
the hydrolysis of GTP (active to inactive) by providing an essential catalytic group.8, 9, 12 The 
other regulator protein, GDIs, are responsible for the activation regulation and control the 
 3 
location of some Rho GTPases within the cell, either in the cytoplasm or on the plasma 
membrane.8, 9, 12 Once a GTPase protein is bound to GTP they have a greater affinity for binding 
to downstream effector proteins. 
Rho GTPases play a significant role in the regulation of cell migration, proliferation, cell 
survival, and apoptosis.9 All of this is necessary for the maintenance of normal tissues, but a 
slight dysregulation could lead to the progression of cancer. The process of oncogenesis, the 
initiation of cancer cells from normal cells, is a multi-step process from environmental and 
genetic factors. This results in an imbalance of certain cellular processes such as, cell 
proliferation or the inhibition of apoptosis leading to the uncontrolled replication of cells i.e., 
immortalization. Cell division control 42 (Cdc42), Ras homolog gene family A (RhoA), and Ras 
related C3 botulinum substrate 1(Rac1) are among some of the Rho subfamily proteins that have 
been identified to play a role in the progression and metastasis of different human tumors.9 
Cdc42 (WT and T35A) 
Cdc42 is a member of the typical Rho GTPase family known to play a significant role in 
cancer progression and is tissue specific. For example, in non-small lung cancer, colorectal, 
adenocarcinoma, melanoma, lung, and breast cancer it has been upregulated, and for kidney, 
central nervous system, and adrenal gland cancers it is downregulated. 
Cdc42 is a small GTPase protein that has a molecular weight of approximately 21kDa 
and its secondary sequence is composed of 6 β sheets and 5 α helices.13, 14 
This protein contains 11 homologs ranging in molecular size from 190 to 193 amino 
acids.10 It contains a particular domain unique among other Ras proteins, known as the Rho-
insert domain (RI) composed of 13 amino acids which serve as a recognition region for 
downstream effectors.14 
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In humans, there are two major isoforms of Cdc42 and they are composed of two main 
regions known as the Switch I (residues 28-41) and Switch II (residues 57-74).1, 7 The Switch I 
and Switch II regions are highly conserved regions among Cdc42 isoforms.1, 7 These two regions 
have demonstrated internal dynamics that allow them to interact with several regulatory and 
effector proteins efficiently. Cdc42 can interact with effector/adaptor proteins such as kinases, 
phospholipases, and actin associated proteins. Cdc42 undergoes post-translational modification 
at the C-terminal side on the Cys residue pivotal for its attachment to the plasma membrane.14 
Downstream effector proteins contain a Cdc42/Rac interactive binding domain (CRIB domain) 
important for the binding of downstream effector proteins with Cdc42 The specificity of the 
effector proteins interaction with Cdc42 is believed to take place with different residues within 
the Switch I region.15 This leads to a competition between effector and regulatory proteins, i.e., 
different interactions at the different times in the cell cycle. 
A single point mutation on Cdc42 wild type (WT) was performed, replacing a Threonine 
with an Alanine at position 35 known as Cdc42(T35A) to study Cdc42 backbone flexibility and 
the overall stability of the protein.7 This mutation was done inside the Switch I region that has 
been recognized to play a role in interacting with downstream effector proteins, upon Cdc42 
being active.1 This single point mutation demonstrated no destruction in the overall tertiary 
structure of the protein and had no effect on its activity.7 Cdc42(T35A) is believed to reduce the 
overall flexibility of the Switch I region.1 This point mutation is significant because Threonine at 
position 35 is highly conserved among all Ras family proteins.1, 7 The point mutation not only 
demonstrated a reduce flexibility with in the Switch I region but a weak interaction was observed 
from a protein known as PBD46.1, 16 This protein is a partial segment of p21-activated 
serine/threonine kinase (PAK1) that interacts with active Cdc42 it was demonstrated to reduce its 
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interaction in comparison with the Cdc42(WT).1, 16, 17 In an in vivo study performed in mammals, 
Cdc42 has been proven to play a significant role in the regulation of the bones and the 
cardiovascular, immune, and nervous systems.18 Cdc42 has the potential to be studied as a model 
for structure-function relationship of cell signaling processes such as actin dynamics, migration, 
survival, and cell cycle progression.8, 19, 20 Additionally, its important role in the progression of 
cancer and other diseases has led current research to focus on small molecules and microRNAs 
as new candidates for treatment.21-23 
Cdc42 in Cancer  
Cancer develops when an accumulation of genetically and epigenetic changes occur on 
tumor suppressor genes and oncogenes.10, 11, 24 Targeted therapeutic treatment depends on the 
specific molecular mechanism responsible for the progression of the disease. Cancer cells are 
unique in their ability to alter the intermediate metabolism. They are able to alter the glycolysis 
pathway by the phosphorylation of the PKM2 enzyme that leads to the formation of lactic acid 
instead of acetyl CoA creating an acidic environment.10 The acidic environment has also been 
related to an increase in tumor progression.10 Cdc42 is usually not mutated in cancer cells but 
rather overexpressed or hyperactivated, and in human cancers they are mainly activated due to an 
upregulation of GEF’s.11, 12, 25, 26 
Cdc42 in its active state has been known to interact with several downstream proteins 
such as PAK, PI3K-AKT, and Raf Merk-Erk pathways.27 Therefore, recent efforts have been 
made to find inhibitory candidates between specific GEF’s and Cdc42.27 ZCL278 is a small 
molecule demonstrated to inhibit the protein intersecting (ITSN), a specific Cdc42 GEF, leading 
to a reduction in cell mobility and the disruption of the Golgi organization.28 Another successful 
derivative from the ZCL compounds is ZCL367 that resulted in a halt of cancer progression in 
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Human A56 lung cancer cells and its high selectivity of Cdc42 in comparison to other Rho 
proteins.27 
Cdc42 can be used as a molecular marker for the identification of early-stage cancers 
such as for the early detection of pancreatic ductal adrenal carcinoma, PDAC.26 Pancreatic 
cancer is known to have no preliminary signs and symptoms, and unfortunately this leads to its 
diagnosis at a later stage with poor prognosis.26 In a study it was found that there is a direct 
relationship between pancreatic carcinogenesis and Cdc42 overexpression.26 
Another recent therapeutic discovery was the use of a small non-coding microRNA 
(miRNA), known to assist in post-transcriptional regulations that play a role in the physiological 
and pathological processes.22, 24, 29 miRNA can serve as therapeutic agents or biomarkers for 
certain cancers. One example is the MicroRNA-548J which has been identified to be 
overexpressed in breast cancer cell lines, known as invasion-inducing miRNA.22 MicroRNA-
548J was demonstrated to activate Tensin1 that is related to the activation of Cdc42.22 The 
selective inhibitor known as ML141 was demonstrated to suppress microRNA-548J mediated 
cell invasion.22 Furthermore, it was demonstrated that microRNA-548J and Tensin1 have a 
strong correlation in regards to breast cancer cell invasion and metastasis.22 
AZA197 
A small organic molecule known as AZA197 was found to suppress tumor growth of 
colon rectal cancer (CRC), and has demonstrated a selectivity of Cdc42 over other Rho proteins.2 
This highlighted the potential of Cdc42 as a candidate for targeted therapies to treat malignancies 
related to its overexpression.2 
Cdc42 has been known to play a key role in the progression of cancer even though it is 
tissue specific. One downstream signal that Cdc42 tends to interact with is PAK1.2 The 
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overexpression of PAK1 has been associated to be an aggressive sign of the CRC disease 
progression.2 Additionality, Cdc42 has also been proven to be overexpressed suggesting a 
potential role in the tumor development.2 In a study using cell lines, SW620 (highly invasive 
colorectal cancer cells) and HT-29 (colorectal cancer cells), it was demonstrated that after being 
treated with AZA197 there was a reduction in cell migration and invasion.2 It was demonstrated 
in the in vivo portion of the study that SW620 colon cancer xenografts had reduced tumor 
growth after being treated with 10 µM AZA197 for twenty days as compared to the control 
xenografts that had not been treated with the small molecule.2 
The synthesis of AZA197 was based on a chemical compound from the National Cancer 
Institute Chemical Database that was used to target against the Rho GTPase protein, Rac A.2 
Using a free docking database known as ZINC, 17 small organic molecules were synthesized by 
a company called SPECS located in the Netherlands.2 All seventeen molecules were carefully 
evaluated and only AZA197 exhibited strong inhibitory activity in SW620 cells.2 The study 
demonstrated that based on a cytotoxicity assay the optimum concentration of AZA197 is 10 
µM. Another assay performed was to identify if the GTPases; Rho, Rac1, and Cdc42 would 
interact with the small molecule in both cell lines.2 This demonstrated that AZA197 specifically 
and significantly downregulates Cdc42 activity in a dosage dependent manner, while there was 
no significant effect on Rac1 or RhoA.2 Next it was determined whether or not AZA197 hinders 
the interaction between Cdc42 and the Dbs protein, a particular Cdc42 GEF protein.2 The 
experiment concluded that AZA197 blocks the interaction of Dbs and Cdc42, halting the 
activation of Cdc42 resulting in its inhibition.2 An in vivo experiment was also performed 
treating mice with SW620 xenografts in the presence and absence of the small molecule for 
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twenty days.2 The results reveled that in the mice that were treated with the small molecule the 
tumor weight was suppressed and resulted in prolonged animal survival.2 
Chapter II-Experimental Methods 
Growth, Expression, and Harvest 
Cdc42(WT) and Cdc42(T35A) constructs are overexpressed using a (N-His6) tag from 
pET15b in Escherichia Coli strain, BL21(DE3), in LB media. In a 500 mL Erlenmeyer flask 
containing 100 mL of LB media, 100 uL of ampicillin (AMP), and a 1 mL bacterial glycerol 
stock, containing 500 uL of 50% glycerol and 500 uL of the overnight culture, was used to make 
an overnight culture growth that was left shaking for 15 hours at a constant speed and 
temperature of 37°C. Upon completion, the overnight culture is used to inoculate a 6 L 
Erlenmeyer flask containing 1.5 L of LB media and 750 uL of AMP utilizing the same 
conditions. For the next couple of hours, the culture was monitored until the optimum optical 
density (OD) was reached, 0.4-0.6. A Varian Cary 50 bioUV-vis Spectroscopy was used to 
measure the OD of the culture at a wavelength of 600 nm. Once the optimal OD was reached, the 
culture was induced with 0.5 mM Isopropyl-beta-D-thioglactopyranoside (IPTG) and was left to 
express for four hours in the shaker under the same conditions. After expression, the cells are 
harvest by centrifugation at 6,500 rpm for 30 minutes at 4oC. The cell pellet is collected, and the 
supernatant is discarded. The cell pellet is resuspended with 1x PBS Buffer solution (pH 7.4) and 
centrifuged again at 4,500 rpm for 12 minutes to washout left over LB media. The supernatant is 
again discarded, and the cell pellet is stored at –80oC. 
Protein Purification 
A 5 mL His-Trap FF column was cleaned and regenerated by the following protocol: 5 cv 
(1 column volume (cv) = 5 mL) of 20% ethanol, 10 cv of deionized water, 3 cv of 1x stripping 
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buffer, 5 cv of deionized water, 3 cv of 1x binding buffer, 2 cv of 1x charging buffer, and 4 cv of 
deionized water. 
A cell pellet was left to thaw on ice and resuspended in lysis buffer. The lysis buffer 
contains: 45 mL of Tris/NaCl binding buffer (40 mM imidazole, 100 mM NaCl, 50 mM Tris (pH 
8.0), and 10 mM MgCl2), 45 mg of lysozyme, 90 uL of phenylmethylsulfonyl fluoride (PMSF), 
160 uL of Halt protease, and a pinch of Bovine DNAse. The cell pellet on ice undergoes a 
sonication cycle, where the sample was sonicated every other ten seconds for five minutes. The 
cell debris and soluble components are separated by centrifugation at 19,000 rpm for 35 minutes. 
The supernatant is collected and filtered and left on ice to prevent proteins degradation. 
The proteins are purified by affinity chromatography using a Fast Protein Liquid 
Chromatography (FPLC) machine. Using the ÄKTA Start system (FPLC, GE Healthcare) with a 
5 mL His-Trap FF column, lysis buffer, binding buffer, and elution buffer were all added into 
their respective place on the FPLC for the protein purification process The column is first 
equilibrated with binding buffer, and upon equilibration the lysis buffer will be passed through 
the column. The lysis buffer interacts with the column and the protein of interest will bind to the 
column while everything else passes through the column. The column is then washed with 
binding buffer to remove unwanted proteins. An increasing linear gradient of elution buffer starts 
to run through the column until 100% of elution buffer has been reached. Allowing for the bound 
protein to come off the column and into the collection tubes. Once this takes place the column is 
re-equilibrated. After the cycle is completed, the column is removed, and everything is cleaned 
according to manufacture protocol. Figure 2.1 represents an example of a chromatogram from 
Cdc42(T35A) after the purification process is complete. The binding phase is illustrated by the 
first peak between 40-65 mL. In which the lysis buffer passes through the column, where all 
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unwanted proteins will elute and the protein of interested will remain in the column. The 
washing phase is between 65-115 mL, where binding buffer is passed through the column to 
make sure any unwanted protein is eluted out of the column. The Elution phase is represented 
from 115-160 mL, where at first a linear gradient of increasing concentration of elution buffer 
will be added to the column to remove the protein of interest. To make sure the protein of 
interest is unbound a 100% elution buffer solution will be added to the column. In this case 
fractions 9-11 where collected. A Chromatograph of the purification of Cdc42(WT)is shown in 
figure 2.2. The binding phase of the purification process was observed between 0-30 mL. The 
washing out phase is demonstrated in the 30-80 mL to ensure the unwanted protein was 
completely washed out. The elution phase is demonstrated in the 80-120 mL, where Cdc42(WT) 
was eluted out, in this case fractions 10-16 where collected. 
 
Figure 2.1. Depicts a chromatogram from the purification of Cdc42(T35A), in this case fractions 
9-11 were collected. The y-axis is a measure of the absorbance units (mAU), and the x-axis 
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represents the volume (mL) used. The blue line depicts the absorbance units, and the pink line 
represents the gradual increase of elution buffer used in order to unbind the protein of interest 
from the column. 
 
 
Figure 2.2. Affinity chromatography showing the purification of Cdc42(WT). The blue line 
depicts the absorbance units (mAU), and the pink line represents the gradual increase of elution 
buffer used in order to unbind the protein of interest from the column. 
 
Once the purification process was completed the collection tubes were collected and 
placed in ice. A 20 uL sample from each collection tube was collected and placed into a 1.5 mL 
microcentrifuge tube with 10 uL of 2X dye to make gel samples to run an SDS-Page. Once the 
gel samples were obtained the collection fraction tubes from the purification were combined and 
added into a dialysis bag with a molecular cut off weight of 4-6 kDa, which was then placed in 
dialysis buffer (100 mM NaCl, 20 mM Tris, and 10 mM MgCl2 (pH of 8.0)) overnight at 4oC. 
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Gel Electrophoresis 
The presence and condition of the protein was confirmed by SDS-Page gel 
electrophoresis. The gel was composed of a 15% bis acrylamide mixture. The 1.5 mL 
microcentrifuge tubes collected from the purification were used, and the gel was run according to 
protocol. Once completed it was washed with water, stained for 10 minutes, and destained 
overnight, then washed with distilled water and scanned. Figure 2.3 reveals a gel obtained from 
two different purifications. The first band represents the molecular weight ladder, where is a set 
of weights standards to identify approximate weights of proteins. The Lys or Lysis buffer is the 
sample obtained before the purification. The flow or flow through represent the washing phase of 
the FPLC, where all of the proteins not bound to the column are eluted out (similar to the peak 
between 65-115 mL in figure 2.1). The 10-14 columns are the actual sample gels collected form 
the elution phase. 
 
Figure 2.3. SDS-PAGE electrophoresis confirming the presence of a Cdc42(WT) based on the 
molecular weight. Two purifications were performed independently from each other. The Lys 
represents the sample obtained before the purification. The flow is the sample obtained during 
the binding phase of the purification, and the numbers correspond to the fractions collected 
during the elution phase of the purification, in this particular case fractions 10-14 were collected.  
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Nucleotide Exchange 
A nucleotide exchange assay was performed to exchange the GTP to a nonhydrolyzable 
form of GTP. The protein was transferred from the dialysis bag into a 15 mL Falcon tube, and 
the concentration was checked with the Bradford protein assay and later corrected using the 
correct molar absorptivity and molecular weight depending on the protein of interest. Once the 
concentration of the protein was obtained, it was then incubated with the GTP analog, β,γ-
Methyleneguanosine 5′-triphosphate sodium salt. The GTP analog serves to conserve the protein 
in its active state. In addition to the GTP analog, 0.5 mM of EDTA is added and left for an 
incubation period of 3.5 hours, at a temperature of 4oC, on a gentle shaker. A desalting column, 
PD-10, was equilibrated with 50 mL of 1X PBS buffer (pH 7.4) and the protein was passed 
through the column and collected in 1 mL microcentrifuge tubes. Each collection tube was 
analyzed using a Bradford Assay to determine its location. Protein Fractions were obtained and 
0.1 M MgCl2 is added to the sample and the concentration was checked and stored at -80oC. 
Chapter III-Experimental Results 
Synthesis of AZA197 
The synthesis of AZA197 was done in collaboration with the McIntosh Group. The 
synthesis involved a two-step reaction. Figure 3.1 illustrate the first step of the reaction 
synthesis, where Tryptamine (2 molar equivalence) and triethylamine (1 molar equivalence) in 
acetonitrile were mixed in a round bottom flask. Once in solution dichloro-6-methylpyrimidine 
(1 molar equivalence) was added. The reaction ran at 70oC for 16 hours. The reaction was 
concentrated and both isomeric products were isolated using a TLC Flash Chromatograph 
AKROS machine. Products were eluted using 60:40 hexane: ethyl acetate, the compounds after 
 14 
being concentrated were a yellow-brown solid. Table 3.1 demonstrates the optimizations used in 
order to obtain the first reaction. 
 
Figure 3.1. Illustrates the first step reaction synthesis. 
 
Table 3.1 Shows the reactions done to optimize the first reaction. 
Tryptamine 
(equivalence) 
2-4-Dichloro-6-
methylpyrimidine 
(equivalence) 
Temperature Time Solvent Successful 
1 2 30oC 17hrs THF No 
1 2 70oC 17hrs THF No 
1 2 70oC 15hrs Triethylamine 
and 
acetonitrile 
Yes 
 
Figures 3.2-3.5 illustrate the proton NMRs obtained for the reaction. Figure 3.2 is a 
proton NMR performed after adding Tryptamine and 2,4-Dichloro-6methylpyrimidine in order 
to obtain a preliminary NMR of the reactants. Figure 3.3 is a proton NMR obtained after the 
reaction was completed and concentrated before the separation of the two isomers. Figures 3.4 
and 3.5 are the proton NMRs after both constitutional isomers where successfully separated and  
concentrated. Figure 3.4 illustrates the isomer of interest, a successfully synthesized AZA197, 1H 
NMR (CDCl3): 2.3(s,3H), 3.08-3.12(t,2H), 3.668(s,2H), 6.01(s,1H), 7.071(s,1H),7.13-
7.16(m,1H), 7.2-7.22(m,1H),7.43-7.405(d,1H),7.64-7.62(d,1H). Figure 3.5 depicts the unwanted 
isomer 1H NMR (CDCl3): 2.3(s,3H), 3.06-3.08(t,2H), 3.7-3.8(t,2H), 6.45(s,1H), 
7.071(s,1H),7.13-7.16(m,1H), 7.2-7.22(m,1H),7.37-7.39(d,1H),7.68-7.7(d,1H). 
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Figure 3.2. Illustrates a Proton NMR of the two reagents added together. Tryptamine and 2-4-Dichloro-6-methylpyrimidine. 
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Figure3.3. Illustrates the proton NMR after the reaction was completed and concentrated. Both Isomers are still not separated. 
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Figure 3.4. Illustrates the isomer of interest after its separation and concentration. The main difference between the constitutional 
isomers are within the peaks on box C and B.  
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Figure 3.5. Illustrates the unwanted isomer after its separation and concentration. The main difference between the constitutional 
isomers are within the peaks on box C and B. 
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The Mass spectra was done after successfully isolating both isomers to confirm that both 
had the corresponding molecular weight of the compounds, which is 286.76 g/mol, and the 
composition of C15H15N4Cl. Figures 3.6 and 3.7 illustrate the mass spectra obtained from the 
wanted isomer and the unwanted isomer, respectively. 
 
Figure 3.6. Illustrates the ESI Mass spectrum obtained for the isomer of interest. 
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Figure 3.7. Illustrates the ESI Mass Spectrum obtained from the isomer that was not 
needed. 
 
For the second step of the reaction synthesis Isomer B and 4-amino-1-
diethylaminopentane were reacted in a 1:1 molar ratio without any solvent as depicted in Figure 
3.8.  
 
 
Figure 3.8. A visual representation of the second step of the reaction synthesis This was 
performed after isomer B has been successfully isolated. 
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The reaction was performed using a CEM Discover microwave machine under the 
following settings: pressure 15 psi, temperature 120oC, and reacted for one hour and 45 minutes. 
The product was a brown solid with a 62% yield. Table 3.2 represents the optimization 
conditions for the second reaction before the final reaction conditions was established. 
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Table 3.2. Optimization conditions for the second reaction. 
Isomer B 
(equivalence) 
4-amino 
-1-
diethylaminopent
ane (equivalence) 
Temperature Time Pressure 
(PSI) 
 Solvent Successful 
1 1.1 130oC 17hrs N/A Oil bath No 
 
No 
1 1.2 60oC 18hrs N/A Oil bath Triethylamine 
and ethanol 
 
No 
1 1.5 70oC 18hrs N/A Oil bath No No 
1 1.5 78oC 20min 30 Microwave 
irradiation 
No No 
1 1.5 78oC 20min 20 Microwave 
irradiation 
No No 
1 1.5 120oC 30min 20 Microwave 
irradiation 
No No 
1 1.5 130oC 30min 25 Microwave 
irradiation 
No No 
1 1.5 130oC 90min 25 Microwave 
irradiation 
No No 
1 1 120oC 1hr40min 15 Microwave 
irradiation 
No Yes 
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Fluorescence experiments 
Using the intrinsic Tryptophan (Trp) in Cdc42(WT) and Cdc42(T35A), fluorescence 
spectroscopy was performed. This was done via a protein denaturation experiment by performing 
an increasing concentration gradient of Guanidine Hydrochloride (GnHCl) in the presence and 
absence of 10 µM AZA197. The data was collected using a Hitachi f2500 fluorometer with an 
excitation wavelength of 280 nm and an emission collection range of 300-400 nm. 
Using the data collected the fraction of denaturation (Fd), equilibrium constant (Keq), 
denaturation concentration (Cm), and Gibbs free energy (∆G) were determined. Fd is obtain by 
equation 1. 
𝐹𝐹𝑑𝑑 =
𝐹𝐹−𝐹𝐹𝑛𝑛
𝐹𝐹𝐷𝐷−𝐹𝐹𝑛𝑛
  (Eq.1) 
F corresponds to the relative fluorescence reading at any given point. Fn is the 
fluorescence reading of the native protein before any denaturant is added. FD, corresponds to the 
fluorescence reading of the completely denatured protein. The equilibrium constant is obtained 
by equation 2. 
𝐾𝐾𝑒𝑒𝑒𝑒 =
𝐹𝐹𝑑𝑑
1−𝐹𝐹𝑑𝑑
  (Eq.2) 
The use of the equilibrium constant can be used to solve for the Gibbs free energy of 
protein unfolding, equation 3.  
∆𝐺𝐺𝑑𝑑 = −𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅(𝐾𝐾𝑒𝑒𝑒𝑒)  (Eq.3) 
The ideal gas constant (R) used was 8.314 J mol-1 K-1, and 298 K was the temperature (T) 
used for the determination of the Gibbs free energy. The use of equation 3 allows us to use 
equation (4) to find the Gibbs free energy of the protein unfolding in the absence of no protein 
denaturant (∆Gd,H2O). 
∆𝐺𝐺𝑑𝑑 = ∆𝐺𝐺𝑑𝑑,𝐻𝐻2𝑂𝑂 − 𝑚𝑚[𝐺𝐺𝑅𝑅𝐺𝐺𝐺𝐺𝐺𝐺]  (Eq.4) 
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To solve for ΔGdH2O (y-intercept), a derivative of the slope-intercept equation is used. The 
slope is represented by m[GnHCl] and changes with respect to increasing [GnHCl]. All 
denaturation experiments were performed in triplicates in the presence and absence of 10 µM 
AZA197 and 100 mL of 1 mg/mL of protein.  
Table 3.1 and Table 3.2 demonstrate the values obtained from the fluorescence 
experiments in the presence and absence of the small molecule AZA197 with increasing 
concentrations of GnHCl. The fluorescence intensity was normalized by using Eq. 1 to find the 
Fd for each point. Since each sample was triplicated the Fd represented is the average of the 
samples and the standard error was obtained in order to used them for error values. The Fd was 
then used to calculate the equilibrium constant (Keq) followed by the determination of Gibbs free 
energy (ΔGd). Figure 3.9 and Figure 3.10 are a graphical representation of the fraction of 
denaturation from Tables 3.3 and Table 3.4, respectively with increasing concentration of GnHCl 
in the presence and absence of AZA197.  
 
Table 3.3 Demonstrates the data used to graph the fractions of denaturation with 
increasing concentration of GnHCl of Cdc42(WT) in the absence and presence of 10 µM 
AZA197, respectively. 
[GnHCl] Cdc42(WT) Fd Standard Error  
Cdc42(WT) + AZA197 
Fd 
Standard 
Error  
0 0 0 0 0 
1 0.3255 0.05977 0.33572 0.04047 
2 0.75437 0.17948 0.556 0.11859 
2.5 0.65448 0.09153 0.61069 0.11734 
3 0.66419 0.05121 0.59782 0.0934 
3.5 0.69207 0.03227 0.62767 0.0496 
4.5 0.7862 0.05696 0.77871 0.08101 
5 0.84542 0.0241 0.93273 0.03363 
5.4 1 0 1 0 
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Figure 3.9 The fraction of denaturation in the absence (red) and presence (black) of 10 
µM AZA197 with increasing concentrations of denaturant (GnHCl) for Cdc42(WT). The 
numerical values used can be found on Table 3.1. The data was analyzed using Origin software. 
 
Table 3.4. Demonstrates the data used to graph the fraction of denaturation with 
increasing concentration of GnHCl of Cdc42(T35A) in the absence and presence of 10 µM 
AZA197, respectively. 
[GnHCl] Cdc(T35A) Fd 
Standard 
Error 
Cdc42(T35A)+ 
AZA197 Fd 
Standard 
Error 
0 0 0 0 0 
1 0.71974 0.01656 0.64858 0.03433 
1.5 0.80246 0.00345 0.73959 0.02023 
2 0.8325 0.01494 0.74068 0.05578 
2.5 0.90647 0.01454 0.78292 0.03707 
3 0.91419 0.01798 0.81606 0.0279 
3.5 0.94599 0.0187 0.83875 0.04071 
4.5 0.97234 0.01332 0.92051 0.02639 
5 1 0 0.97471 0.00943 
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Figure 3.10. The fraction of denaturation in the absence (red) and presence (black) of 10 
µM AZA197 with increasing concentrations of denaturant (GnHCl) for Cdc42(T35A). The 
numerical values used can be found on Table 3.2. The data was analyzed using Origin software. 
 
The Cm is the concentration of the denaturant were the folded and unfolded proteins are 
in equilibrium. The Fd of 0.5 was used to determine the Cm values for each data set. As seen in 
Table 3.5 the Cm values of Cdc42(WT) and Cdc42(T35A) implies that there is no significant 
change in the presence and absence of AZA197. This suggest that AZA197 does not have an 
effect on the overall stability of the proteins. 
Table 3.5 Cm values in the presence and absence of AZA197 for Cdc42(WT) and Cdc42(T35A). 
 Cm 
Cdc42(WT) 1.49 
Cdc42(WT) + AZA197 1.37 
Cdc42(T35A) 0.69 
Cdc42(T35A) + AZA197 0.75 
 
Tables 3.6 and Table 3.7 Exhibit the Gibbs free energy in respects to increasing 
concentration of GnHCl in the presence and absence of 10 µM AZA197 for Cdc42(WT) and 
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Cdc42(T35A), respectively. Figure 3.11 and figure 3.12 are a graphical representation of the 
Gibs free energy of the Tables 3.6 and 3.7, respectively.  
Table 3.6. The Gibbs free energy of protein unfolding in the absence of the denaturant 
for Cdc42(WT) 
[GnHCl]   ΔGd Cdc42(WT)   ΔGd Cdc42(WT) + AZA197  
1 1805.1416 1692.172 
1.5 -335.7254 -1116.369 
2.5 -1582.294 -982.8852 
3 -1689.776 -1294.915 
3.5 -2006.36 -3119.765 
4.5 -3226.281 -6520.107 
 
 
 
Figure 3.11. The denatured Gibbs free energy (ΔGd) of Cdc42(WT)in the presence and 
absence of AZA197 in respect to increasing concentrations of GnHCl. The data points were 
derived from the Fd. The data was analyzed using Origin software. 
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Table 3.7. The Gibbs free energy of the protein unfolding in the absence of the denaturant. For 
Cdc42(T35A). 
[GnHCl]  ΔGd Cdc(T35A)   ΔGd Cdc(T35A)+ AZA197 
1 -969.7889 -1518.399 
2 -2336.356 -2600.4174 
2.5 -3973.171 -3178.3404 
3 -5626.093 -3691.4551 
3.5 -5860.508 -4085.7334 
4.5 -7092.292 -6068.7436 
 
 
 
Figure 3.12. The denatured Gibbs free energy (ΔGd) of Cdc42(T35A)in the presence and 
absence of AZA197 in respect to increasing concentrations of GnHCl. The data points were 
derived from the Fd. The data was analyzed using Origin software. 
 
For Cdc42 (WT) Keq and ∆Gd have a significant difference suggesting that in the 
presence of the small molecule seems to have an influence. As its signified in Table 3.8, in the 
presence of the small molecule there is an increase in ∆Gd,H2O and the slope, meaning that in the 
presence of AZA197 it unfolds at a slower rate. For Cdc42(T35A), the small molecule seems to 
have an opposite influence on unfolding relative to the wild type. There is a significant change in 
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the Fd, Keq, and ∆Gd. Suggesting that AZA197 destabilizes Cdc42(T35A), not interacting in the 
same manner as compared to the wild type. 
Table 3.8. The Gibbs free energy of unfolding in the absence of no protein denaturant 
and its corresponding slope determined by Eq.4 
 DGd,H2O (kJ/mol) m[GnHCl] (kJ/L) 
Cdc42(WT) 2.587 -1.367 
Cdc42(WT)+AZA197 4.057 -2.162  
Cdc42(T35A) 0.825 -1.867 
Cdc42(T35A) +AZA197 -0.09134 -1.248 
 
Chapter IV-Conclusion 
The biophysical characterizations of the small molecule, AZA197, and Cdc42 are 
important for its potential use as an anticancer drug therapy. It has been demonstrated that Cdc42 
is tissue specific, and it can be either be upregulated or downregulated in cancer. In those 
malignancies that have been associated with Cdc42 upregulation, small molecules have been 
used to inhibit the interaction with downstream effector proteins, reducing its overactivity. 
The discovery of the small molecule AZA197 demonstrates its potential use as an 
anticancer drug therapy as it has high selectivity to Cdc42 among other Rho related proteins. 
Nonetheless, to understand Cdc42 and AZA197 interactions at a molecular level, more 
biophysical characterizations need to be performed. AZA197 was synthesized and its interactions 
with Cdc42(WT) and Cdc42(T35A) were studied with increasing concentrations of GnHCl. 
This biophysical characterization demonstrated that Cdc42(WT) is more stable in the 
presence of the small molecule under increasing concentrations of the denaturant. The Gibbs free 
energy of the protein unfolding was determined via fluorescence experiments, and an increase 
was demonstrated in the presence of AZA197. 
This suggested that AZA197 helps stabilize Cdc42(WT). In contrast, the fluorescence 
denaturation experiments with Cdc42(T35A) in the presence and absence of the small molecule 
 
30 
has a negative effect making it more destabilized in comparison to Cdc42(WT). This data 
suggested that Cdc42(T35A) has no positive interaction with AZA197. Cdc42(T35A) is in the 
Switch I region that is highly conserved in Cdc42(WT), where its flexibility allows for its 
interactions with downstream effector proteins once the protein is in the active state. The data 
suggest that AZA197 binds to the Switch I region which could lead to a potential inhibition to its 
overall activity.  
However, to better understand the molecular interactions of Cdc42(WT) and 
Cdc42(T35A) with AZA197 more experiments should be performed. Future experiments that 
could give a better understanding of its interactions would be a time-dependent fluorescence 
denaturation experiment, Isothermal Calorimetry (ITC), NMR, and GTP hydrolysis. These 
would allow for the understanding of the interactions between Cdc42 and AZA197 at a 
molecular level to determine AZA197’s potential as an anticancer drug therapy. 
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